Editorial: co-morbid gastrointestinal conditions are an important consideration in IBS management-authors' reply

Christopher J Black^{1

2}, Alexander C Ford^{1

2}

Affiliations

¹ Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.
² Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.

Editorial

Christopher J Black et al. Aliment Pharmacol Ther. 2021 May.

. 2021 May;53(10):1153-1154.

doi: 10.1111/apt.16351.

Christopher J Black^{1

2}, Alexander C Ford^{1

2}

¹ Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.
² Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.

No abstract available

Comment on

Longitudinal follow-up of a novel classification system for irritable bowel syndrome: natural history and prognostic value.
Black CJ, Yiannakou Y, Guthrie E, West R, Houghton LA, Ford AC. Black CJ, et al. Aliment Pharmacol Ther. 2021 May;53(10):1126-1137. doi: 10.1111/apt.16322. Epub 2021 Mar 11. Aliment Pharmacol Ther. 2021. PMID: 33705578
Editorial: co-morbid gastrointestinal conditions are an important consideration in IBS management.
Simons M, Taft TH. Simons M, et al. Aliment Pharmacol Ther. 2021 May;53(10):1151-1152. doi: 10.1111/apt.16345. Aliment Pharmacol Ther. 2021. PMID: 33882166 No abstract available.

1. Black CJ, Yiannakou Y, Guthrie E, et al. Longitudinal follow-up of a novel classification system for irritable bowel syndrome: natural history and prognostic value. Aliment Pharmacol Ther. 2021;53:1126-1137.
1. Black CJ, Yiannakou Y, Guthrie EA, West R, Houghton LA, Ford AC. A novel method to classify and subgroup patients with IBS based on gastrointestinal symptoms and psychological profiles. Am J Gastroenterol. 2021;116:372-381.
1. Barberio B, Pinto-Sanchez MI, Bercik P, et al. Derivation and validation of a novel method to subgroup patients with functional dyspepsia: beyond upper gastrointestinal symptoms. Aliment Pharmacol Ther. 2021;53:253-264.
1. Gracie DJ, Williams CJ, Sood R, et al. Negative effects on psychological health and quality of life of genuine irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2017;15:376-384.e5.
1. Fairbrass KM, Costantino SJ, Gracie DJ, Ford AC. Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:1053-1062.